Answers are grounded in this paper and cite their sources.
This article aimed to assess the effect of botulinum toxin type A (BTX-A), when used in conjunction with physiotherapy, in spasticity management. Patients were assessed before and after BTX-A injection using the following outcome measures: the Medical Research Council (MRC) scale for motor testing; the Modified Ashworth Scale (MAS) for spasticity; the Global Pain Scale (GPS); the modified Barthel score for activities of daily living; spasm frequency; and adductor tone rating. In total, 72 patients (aged 13–81 years; 43% male) received BTX-A treatment. MAS scores were reduced by a median of 1 point (P <0.001) and 56% of patients had a 30% or greater reduction in GPS scores after injection. Mean spasm frequency (per hour) was reduced by 3.1 (P <0.001) and improvements were detected in adductor tone and activities of daily living scores (P <0.001 and P=0.046 respectively) after injection, while MRC scale scores showed statistically significant improvements, particularly in severely impacted categories (P=0.007). Reported improvements in affected joints were made by patients and carers, with benefits lasting an average of 6 months. BTX-A injections were well tolerated. These findings suggest that BTX-A injections have a key role to play in spasticity management.
No takes yet. Share an insight, caveat, or question.
Jai Kulkarni (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: